Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group

Eur J Cancer. 1998 Nov;34(12):1922-6. doi: 10.1016/s0959-8049(98)00288-3.


The recent isolation of breast cancer predisposing genes (BRCA1 and BRCA2) allows the identification of carriers within affected families. These carriers have a 50-85% risk of developing breast or ovarian cancer and need careful follow-up. The purpose of this study was to evaluate the management and screening protocols implemented in high risk families at various family cancer clinics in Europe. A questionnaire was mailed to the members of the European Familial Breast Cancer Collaborative Group (n = 30) requesting information on the following issues: indication for surveillance of breasts and ovaries, the recommended protocol, coordination of the screening examination, prophylactic surgery, the specific management of breast cancer in a mutation carrier and the use of oestrogen. 16 centres from nine countries responded. Most centres recommend surveillance of the breasts if the lifetime risk exceeds 15-20%. The surveillance protocol that is generally advised comprises monthly self breast examination, examination by a specialist every 6 months and annual mammography, all starting from an age between 25 and 35 years. Surveillance of the ovaries is recommended in BRCA1 and BRCA2-mutation carriers, in members from breast/ovarian cancer families and in some centres in 'breast cancer only' families with an early onset of breast cancer. The recommended protocol includes gynaecological examination, sonography and estimation of CA-125 at yearly intervals starting from the age 30-35 years. Prophylactic mastectomy is considered for proven mutation carriers in some centres. Most centres consider prophylactic oophorectomy in mutation carriers and some centres also consider it for members of breast/ovarian cancer families. This survey provides insight into the guidelines for surveillance and management of familial breast cancer used at various family cancer clinics in Europe; this insight may contribute to the appropriate management of these high risk women. It should be emphasised that most recommendations are based on experts' opinion rather than on any specific studies.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • BRCA2 Protein
  • Breast Neoplasms / genetics
  • Breast Neoplasms / prevention & control*
  • Breast Neoplasms / surgery
  • Contraceptives, Oral / adverse effects
  • Europe
  • Female
  • Genes, BRCA1 / genetics*
  • Genetic Testing / methods
  • Humans
  • Mastectomy / methods
  • Mutation / genetics
  • Neoplasm Proteins / genetics*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / prevention & control*
  • Ovarian Neoplasms / surgery
  • Ovariectomy / methods
  • Pedigree
  • Risk Factors
  • Transcription Factors / genetics*


  • BRCA2 Protein
  • Contraceptives, Oral
  • Neoplasm Proteins
  • Transcription Factors